Mark Pap Technology PAST PRESENT AND FUTURE Bio

Mark. Pap Technology PAST, PRESENT AND FUTURE Bio. Sci. Con, 2007 Business Overview 2007

Bio. Sci. Con, Inc. Bio. Sci. Con is a women-owned small business company that has developed and has rights to manufacture, market and sale patented biomarker-based Mark. Pap® technology products intended for cytological early detection of cervical cancer/pre-cancer. Mark. Pap technology is more accurate, faster and less costly than current Pap test technologies. 10/27/2021 Business Overview 2007 2

Mark. Pap® technology: Biomarker makes a difference Mark. Pap biomarker is cytoplasmic expression of genetic changes in cervical cells during transformation from normal to pre-malignant (dysplastic) and malignant, with or w/o HPV infection. When visualized with Mark. Pap test biomarker appears as a red pigment flagging only abnormal cells. 10/27/2021 Business Overview 2007 3

Mark. Pap test applied in Pap test as a new ancillary method Abnormal specimen, ASC-H. Three small abnormal (red) cells among several normal cells. Screening magnification (left). Diagnostic magnifications (right). Abnormal cells cannot be missed! 10/27/2021 Business Overview 2007 4

Biomarker is positive in cancer and HPV induced abnormal cells Mark. Pap smear from a patient with invasive cervical carcinoma HPV positive. • Red biomarker is positive in all abnormal cells where microvacuolization and dysplastic features are present together 10/27/2021 Business Overview 2007 5

Mark. Pap screening and HPV vaccines Cervical cancer was the major killer of women with malignant diseases. Measures for prevention and control, such as mass screening with low-cost and accurate methods such as Mark. Pap, with added benefit of HPV vaccines, raise hopes for cervical cancer eradication in the years to come. 10/27/2021 Business Overview 2007 6

CLINICAL TRIALS RESULTS 2, 000 s/s NEW CTR-2 LBP Th. P Advantage CAP CTR-1 Pap Ancillary Mark. Pap CAP+PAP Pap Th. P D-Ac, Se, FN Diagnostic Accuracy* Sensitivity 0. 93 0. 51 0. 82 1. 8: 1: 1. 6 0. 88 0. 51 0. 8 1. 7: 1: 1. 5 False negative 4 18 17 1: 5: 4 10/27/2021 Business Overview 2007 CAP+PAP 7

Intellectual Property Market protection Mark. Pap is currently protected: 1. Parent patent US PTO # 6, 143, 512 Granted November 2000 2. Patent pending 3. International Application (PCT 2004) 4. Trademark Mark. Pap® Continuing developments: 5. Digital Mark. Pap (Tele. Pap) 6. Mark. Pap for home self-testing (Home. Pap) 10/27/2021 Business Overview 2007 8

Competitive Mark. Pap® advantages on the market • Better accuracy for lower cost • Better productivity for less liability • Mass cervical cancer screening worldwide with Home. Pap and Tele. Pap Huge societal benefit saving women’s lives with enormous market and incredible potential for profit. www. bioscicon. com 10/27/2021 Business Overview 2007 9

Market Opportunity – WORLD 1. 7 billion women at risk US/EU China 250 M 300 M Risk Developing Countries 1. 4 Billion Women at Risk 10/27/2021 Developing countries • 1, 400 M women at risk • 100 M test per year • Outreach 6. 5% China • 300 M women at risk • 72 M test and growing • Outreach 24% US & EU • 250 M women at risk • 95 M tests annually • 3 -5 B dollars market • Outreach: ~80% at 3 years Business Overview 2007 10

Returns to investors Negotiable terms for investment: • Percent of profit on sales of the product (royalty) • Percent interest in the Mark. Pap LLC (equity investment) • Interest on investment Bio. Sci. Con offers all options to investors. 10/27/2021 Business Overview 2007 11

Mark. Pap technology in the next decade Towards this vision, we are developing a palette of products which are unique because they are based on the proprietary biomarker. They include new types of specimen collection (Mark. Pap Self), digital imaging for fast, reliable and low-cost diagnosis at distance (Mark. Pap Digital) and automation for specimen processing, reading and interpretation (Mark. Pap Auto). New products as Mark. Pap Cervical Cell Bank are envision to provide material for further basic research and new drug development 10/27/2021 Business Overview 2007 12

Bio. Sci. Con in the next decade • Bio. Sci. Con ultimate goal is the Home. Tele. Pap test for global cervical cancer screening, monitoring of the effects of HPV vaccination and saving thousands of women’s lives. • The business arm Mark. Pap LLC to manufacture, market, distribute and sale Mark. Pap technology products • Independent non-profit corporation to collect and organize past, present and future Bio. Sci. Con activities for the advancement of education and science on women’s health. 10/27/2021 Business Overview 2007 13

Acknowledgement The National Institutes of Health NIH SBIR Program (1 R 43 CA 86767 -01, 1 R 43 CA 094628 01, 2 R 44 CA 086767 -02) NIH Commercialization Assistance Program Larta Institute, San Francisco, CA 10/27/2021 Business Overview 2007 14

Bio. Sci. Con, Inc. Mark. Pap, LLC 14905 Forest Landing Circle Rockville, MD 20850 Shady Grove Development Park, Gaithersburg, MD 20877 Frederick Innovation Technology Center, Frederick, MD 21701 Te. L: 301 -61 -9130 Fax: 301 -610 -7662 Web site: www. bioscicon. com E-mail: info@bioscicon. com 10/27/2021 Business Overview 2007 15